Application of immunosignatures to the assessment of Alzheimer's disease.
Identifieur interne : 001E53 ( PubMed/Corpus ); précédent : 001E52; suivant : 001E54Application of immunosignatures to the assessment of Alzheimer's disease.
Auteurs : Lucas Restrepo ; Phillip Stafford ; D Mitch Magee ; Stephen Albert JohnstonSource :
- Annals of neurology [ 1531-8249 ] ; 2011.
English descriptors
- KwdEn :
- Alzheimer Disease (diagnosis), Alzheimer Disease (immunology), Amyloid beta-Peptides (genetics), Amyloid beta-Peptides (immunology), Animals, Antibodies (immunology), Diagnostic Techniques, Neurological, Humans, Immunoassay (methods), Mice, Mice, Transgenic, Microarray Analysis (methods), Peptides (genetics), Peptides (immunology), tau Proteins (genetics), tau Proteins (immunology).
- MESH :
- chemical , genetics : Amyloid beta-Peptides, Peptides, tau Proteins.
- diagnosis : Alzheimer Disease.
- immunology : Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Peptides, tau Proteins.
- methods : Immunoassay, Microarray Analysis.
- Animals, Diagnostic Techniques, Neurological, Humans, Mice, Mice, Transgenic.
Abstract
Accurate assessment of Alzheimer's disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may be used for a simple diagnostic test.
DOI: 10.1002/ana.22405
PubMed: 21823156
Links to Exploration step
pubmed:21823156Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Application of immunosignatures to the assessment of Alzheimer's disease.</title><author><name sortKey="Restrepo, Lucas" sort="Restrepo, Lucas" uniqKey="Restrepo L" first="Lucas" last="Restrepo">Lucas Restrepo</name><affiliation><nlm:affiliation>Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ 85287-5901, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Stafford, Phillip" sort="Stafford, Phillip" uniqKey="Stafford P" first="Phillip" last="Stafford">Phillip Stafford</name></author><author><name sortKey="Magee, D Mitch" sort="Magee, D Mitch" uniqKey="Magee D" first="D Mitch" last="Magee">D Mitch Magee</name></author><author><name sortKey="Johnston, Stephen Albert" sort="Johnston, Stephen Albert" uniqKey="Johnston S" first="Stephen Albert" last="Johnston">Stephen Albert Johnston</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21823156</idno><idno type="pmid">21823156</idno><idno type="doi">10.1002/ana.22405</idno><idno type="wicri:Area/PubMed/Corpus">001E53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E53</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Application of immunosignatures to the assessment of Alzheimer's disease.</title><author><name sortKey="Restrepo, Lucas" sort="Restrepo, Lucas" uniqKey="Restrepo L" first="Lucas" last="Restrepo">Lucas Restrepo</name><affiliation><nlm:affiliation>Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ 85287-5901, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Stafford, Phillip" sort="Stafford, Phillip" uniqKey="Stafford P" first="Phillip" last="Stafford">Phillip Stafford</name></author><author><name sortKey="Magee, D Mitch" sort="Magee, D Mitch" uniqKey="Magee D" first="D Mitch" last="Magee">D Mitch Magee</name></author><author><name sortKey="Johnston, Stephen Albert" sort="Johnston, Stephen Albert" uniqKey="Johnston S" first="Stephen Albert" last="Johnston">Stephen Albert Johnston</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="eISSN">1531-8249</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer Disease (diagnosis)</term><term>Alzheimer Disease (immunology)</term><term>Amyloid beta-Peptides (genetics)</term><term>Amyloid beta-Peptides (immunology)</term><term>Animals</term><term>Antibodies (immunology)</term><term>Diagnostic Techniques, Neurological</term><term>Humans</term><term>Immunoassay (methods)</term><term>Mice</term><term>Mice, Transgenic</term><term>Microarray Analysis (methods)</term><term>Peptides (genetics)</term><term>Peptides (immunology)</term><term>tau Proteins (genetics)</term><term>tau Proteins (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Amyloid beta-Peptides</term><term>Peptides</term><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Alzheimer Disease</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Alzheimer Disease</term><term>Amyloid beta-Peptides</term><term>Antibodies</term><term>Peptides</term><term>tau Proteins</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunoassay</term><term>Microarray Analysis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Diagnostic Techniques, Neurological</term><term>Humans</term><term>Mice</term><term>Mice, Transgenic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Accurate assessment of Alzheimer's disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may be used for a simple diagnostic test.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21823156</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Application of immunosignatures to the assessment of Alzheimer's disease.</ArticleTitle><Pagination><MedlinePgn>286-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.22405</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Accurate assessment of Alzheimer's disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may be used for a simple diagnostic test.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed an array-based system to profile the antibody repertoire of transgenic mice with cerebral amyloidosis (TG) and elderly individuals with or without AD. The array consists of 10,000 random sequence peptides (20-mers) capable of detecting antibody binding patterns, allowing the identification of peptides that mimic epitopes targeted by a donor's serum.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">TG mice exhibited a distinct immunoprofile compared to nontransgenic littermates. Further, we show that dementia patients, including autopsy-confirmed AD subjects, have distinguishable profiles compared to age-matched nondemented people. Using antibodies to different forms of Aβ peptide and blocking protocols, we demonstrate that most of this signature is not due to the subject's antibodies raised against Aβ.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">We propose that "immunosignaturing" technology may have potential as a diagnostic tool in AD.</AbstractText><CopyrightInformation>Copyright © 2011 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Restrepo</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Innovations in Medicine, Biodesign Institute, Arizona State University, Tempe, AZ 85287-5901, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stafford</LastName><ForeName>Phillip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Magee</LastName><ForeName>D Mitch</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Stephen Albert</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003943" MajorTopicYN="Y">Diagnostic Techniques, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21823156</ArticleId><ArticleId IdType="doi">10.1002/ana.22405</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21823156
|texte= Application of immunosignatures to the assessment of Alzheimer's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21823156" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |